{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ann+Arbor+Stage+IV+Hodgkin+Lymphoma", "query": { "condition": "Ann Arbor Stage IV Hodgkin Lymphoma" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 36, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ann+Arbor+Stage+IV+Hodgkin+Lymphoma&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-05-21T21:58:12.831Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06442475", "title": "Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ann Arbor Stage II Follicular Lymphoma", "Ann Arbor Stage II Marginal Zone Lymphoma", "Ann Arbor Stage III Follicular Lymphoma", "Ann Arbor Stage III Marginal Zone Lymphoma", "Ann Arbor Stage IV Follicular Lymphoma", "Ann Arbor Stage IV Marginal Zone Lymphoma", "Grade 1 Follicular Lymphoma", "Grade 2 Follicular Lymphoma", "Grade 3a Follicular Lymphoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Mosunetuzumab", "type": "BIOLOGICAL" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "OTHER" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2024-08-29", "completion_date": "2027-02-12", "has_results": false, "last_update_posted_date": "2026-03-13", "last_synced_at": "2026-05-21T21:58:12.831Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT06442475" }, { "nct_id": "NCT05025800", "title": "ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Aggressive B-Cell Non-Hodgkin Lymphoma", "Ann Arbor Stage III Grade 2 Follicular Lymphoma", "Ann Arbor Stage III Grade 3 Follicular Lymphoma", "Ann Arbor Stage III Marginal Zone Lymphoma", "Ann Arbor Stage IV Grade 1 Follicular Lymphoma", "Ann Arbor Stage IV Grade 2 Follicular Lymphoma", "Ann Arbor Stage IV Grade 3 Follicular Lymphoma", "Ann Arbor Stage IV Marginal Zone Lymphoma", "Composite Lymphoma", "Indolent B-Cell Non-Hodgkin Lymphoma", "Refractory Aggressive B-Cell Non-Hodgkin Lymphoma", "Refractory Follicular Lymphoma", "Refractory Grade 3b Follicular Lymphoma", "Refractory High Grade B-Cell Lymphoma", "Refractory Mantle Cell Lymphoma", "Refractory Marginal Zone Lymphoma", "Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma", "Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma", "Refractory Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma", "Richter Syndrome" ], "interventions": [ { "name": "CD47 Antagonist ALX148", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 47, "start_date": "2021-10-13", "completion_date": "2028-03-21", "has_results": false, "last_update_posted_date": "2026-03-20", "last_synced_at": "2026-05-21T21:58:12.831Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05025800" }, { "nct_id": "NCT06745076", "title": "Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Hodgkin Lymphoma", "Classic Hodgkin Lymphoma", "Lugano Classification Stage III Hodgkin Lymphoma AJCC v8", "Lugano Classification Stage IV Hodgkin Lymphoma AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Dacarbazine", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Vinblastine", "type": "DRUG" }, { "name": "Questionnaire", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 125, "start_date": "2025-03-06", "completion_date": "2033-01-03", "has_results": false, "last_update_posted_date": "2026-03-05", "last_synced_at": "2026-05-21T21:58:12.831Z", "location_count": 5, "location_summary": "Irvine, California • Boston, Massachusetts • St Louis, Missouri + 2 more", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT06745076" }, { "nct_id": "NCT00822120", "title": "S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma", "Nonneoplastic Condition" ], "interventions": [ { "name": "bleomycin sulfate", "type": "BIOLOGICAL" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "ABVD regimen", "type": "DRUG" }, { "name": "BEACOPP regimen", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "dacarbazine", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "procarbazine hydrochloride", "type": "DRUG" }, { "name": "vinblastine sulfate", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 371, "start_date": "2009-07", "completion_date": "2022-06-30", "has_results": true, "last_update_posted_date": "2022-08-18", "last_synced_at": "2026-05-21T21:58:12.831Z", "location_count": 423, "location_summary": "Tucson, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 290 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00822120" }, { "nct_id": "NCT01145495", "title": "Lenalidomide and Rituximab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma", "Ann Arbor Stage II Grade 1 Non-Contiguous Follicular Lymphoma", "Ann Arbor Stage II Grade 2 Contiguous Follicular Lymphoma", "Ann Arbor Stage II Grade 2 Non-Contiguous Follicular Lymphoma", "Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma", "Ann Arbor Stage II Grade 3 Non-Contiguous Follicular Lymphoma", "Ann Arbor Stage III Grade 1 Follicular Lymphoma", "Ann Arbor Stage III Grade 2 Follicular Lymphoma", "Ann Arbor Stage III Grade 3 Follicular Lymphoma", "Ann Arbor Stage IV Grade 1 Follicular Lymphoma", "Ann Arbor Stage IV Grade 2 Follicular Lymphoma", "Ann Arbor Stage IV Grade 3 Follicular Lymphoma" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" } ], "intervention_types": [ "OTHER", "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 66, "start_date": "2010-06-15", "completion_date": "2022-01-15", "has_results": true, "last_update_posted_date": "2023-06-27", "last_synced_at": "2026-05-21T21:58:12.831Z", "location_count": 91, "location_summary": "Mountain View, California • Palo Alto, California • Lewes, Delaware + 66 more", "locations": [ { "city": "Mountain View", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Lewes", "state": "Delaware" }, { "city": "Newark", "state": "Delaware" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01145495" }, { "nct_id": "NCT02489123", "title": "Enzalutamide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ann Arbor Stage I Mantle Cell Lymphoma", "Ann Arbor Stage II Mantle Cell Lymphoma", "Ann Arbor Stage III Mantle Cell Lymphoma", "Ann Arbor Stage IV Mantle Cell Lymphoma", "Recurrent Mantle Cell Lymphoma", "Refractory Mantle Cell Lymphoma" ], "interventions": [ { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2015-08-11", "completion_date": "2020-06-16", "has_results": true, "last_update_posted_date": "2021-08-10", "last_synced_at": "2026-05-21T21:58:12.831Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT02489123" }, { "nct_id": "NCT03213691", "title": "Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Malignant Solid Neoplasm", "Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma", "Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma", "Recurrent Childhood Central Nervous System Neoplasm", "Recurrent Childhood Non-Hodgkin Lymphoma", "Recurrent Malignant Solid Neoplasm", "Recurrent Neuroblastoma", "Refractory Malignant Solid Neoplasm", "Refractory Neuroblastoma", "Refractory Non-Hodgkin Lymphoma", "Refractory Primary Central Nervous System Neoplasm" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Selumetinib", "type": "DRUG" }, { "name": "Selumetinib Sulfate", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "21 Years", "sex": "ALL", "summary": "12 Months to 21 Years" }, "enrollment_count": 21, "start_date": "2017-10-30", "completion_date": "2024-12-31", "has_results": true, "last_update_posted_date": "2025-02-05", "last_synced_at": "2026-05-21T21:58:12.831Z", "location_count": 108, "location_summary": "Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 84 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Downey", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03213691" }, { "nct_id": "NCT01771107", "title": "Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "AIDS-Related Hodgkin Lymphoma", "Ann Arbor Stage II Hodgkin Lymphoma", "Ann Arbor Stage IIA Hodgkin Lymphoma", "Ann Arbor Stage IIB Hodgkin Lymphoma", "Ann Arbor Stage III Hodgkin Lymphoma", "Ann Arbor Stage IIIA Hodgkin Lymphoma", "Ann Arbor Stage IIIB Hodgkin Lymphoma", "Ann Arbor Stage IV Hodgkin Lymphoma", "Ann Arbor Stage IVA Hodgkin Lymphoma", "Ann Arbor Stage IVB Hodgkin Lymphoma", "Classic Hodgkin Lymphoma", "HIV Infection" ], "interventions": [ { "name": "Brentuximab Vedotin", "type": "DRUG" }, { "name": "Dacarbazine", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Vinblastine", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2013-03-08", "completion_date": "2024-03-21", "has_results": true, "last_update_posted_date": "2025-08-15", "last_synced_at": "2026-05-21T21:58:12.831Z", "location_count": 20, "location_summary": "La Jolla, California • Los Angeles, California • Sacramento, California + 10 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01771107" }, { "nct_id": "NCT03749018", "title": "Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Aggressive Non-Hodgkin Lymphoma", "Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma", "Ann Arbor Stage II B-Cell Non-Hodgkin Lymphoma", "Ann Arbor Stage II Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma", "Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma", "Ann Arbor Stage III Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma", "Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma", "Ann Arbor Stage IV Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma", "Diffuse Large B-Cell Lymphoma", "High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements", "High Grade B-Cell Lymphoma, Not Otherwise Specified", "Indolent Non-Hodgkin Lymphoma", "Mediastinal B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma", "Transformed Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Vincristine Sulfate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "David Bond, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2019-01-02", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-02-06", "last_synced_at": "2026-05-21T21:58:12.831Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03749018" }, { "nct_id": "NCT01193842", "title": "Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "AIDS-Related Plasmablastic Lymphoma", "AIDS-Related Primary Effusion Lymphoma", "Ann Arbor Stage I Diffuse Large B-Cell Lymphoma", "Ann Arbor Stage I Grade 3 Follicular Lymphoma", "Ann Arbor Stage II Diffuse Large B-Cell Lymphoma", "Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma", "Ann Arbor Stage II Grade 3 Non-Contiguous Follicular Lymphoma", "Ann Arbor Stage III Diffuse Large B-Cell Lymphoma", "Ann Arbor Stage III Grade 3 Follicular Lymphoma", "Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma", "Ann Arbor Stage IV Grade 3 Follicular Lymphoma", "HIV Infection", "Plasmablastic Lymphoma", "Primary Effusion Lymphoma", "Recurrent Diffuse Large B-Cell Lymphoma", "Recurrent Grade 3 Follicular Lymphoma" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Vincristine Sulfate", "type": "DRUG" }, { "name": "Vorinostat", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 107, "start_date": "2010-10-06", "completion_date": "2022-05-19", "has_results": true, "last_update_posted_date": "2023-11-21", "last_synced_at": "2026-05-21T21:58:12.831Z", "location_count": 35, "location_summary": "Montgomery, Alabama • La Jolla, California • Los Angeles, California + 16 more", "locations": [ { "city": "Montgomery", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01193842" } ] }